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Abstract
Cancer therapy using oncolytic viruses is an emerging area, in which viruses are
engineered to selectively propagate in tumor tissues without affecting healthy cells.
Because of the advantages that adenoviruses (Ads) have over other viruses, they are
more considered. To achieve tumor selectivity, two main modifications on Ads
genome have been applied: small deletions and insertion of tissue‐ or tumor‐specific
promoters. Despite oncolytic adenoviruses ability in tumor cell lysis and immune
responses stimulation, to further increase their antitumor effects, genomic modifica-
tions have been carried out including insertion of checkpoint inhibitors and antigenic
or immunostimulatory molecules into the adenovirus genome and combination with
dendritic cells and chemotherapeutic agents. This study reviews oncolytic adeno-
viruses structures, their antitumor efficacy in combination with other therapeutic
strategies, and finally challenges around this treatment approach.
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1 | INTRODUCTION
Despite attempts and advances in treatment, cancer remains one of
the leaders of mortality and morbidity worldwide and has many
adverse socioeconomic effects (Viegas, Ladeira, Costa‐Veiga,
Perelman, & Gajski, 2017). In addition to chemotherapy and
radiotherapy that are considered as conventional cancer treat-
ments, other approaches have been emerged to combat cancer such
as immunotherapy and virotherapy (Simpson, Relph, Harrington,
Melcher, & Pandha, 2016). Although Oncorine (H101), an oncolytic
adenovirus, was approved by Chinese state FDA for head and neck
carcinomas in 2005, the fist approved oncolytic virus by FDA was a
genetically engineered herpes simplex virus named talimogene
laherparepvec, which was approved in 2015 for melanoma patients
(Gopisankar & Surendiran, 2018). Among different viruses, using
adenoviruses (Ads) have attracted much attention because of their
ability to grow in high titers in vitro, to replicate in episomal form,
and to upregulate costimulatory molecules and induce chemokine
and cytokine responses, which introduce them as “nature’s
adjuvants” (Robert‐Guroff, 2007). The Ads were first isolated in
1953 from human adenoid cells (Rowe, Huebner, Gilmore, Parrott,
& Ward, 1953) and thus far, more than 100 species have been
identified, and of them, human Ads are classified into seven
subgroups (A–G). Among them, serotype 5 (Ad5) which belongs to
subgroup C is more extensively used in gene therapy and
virotherapy (Rux & Burnett, 2004). This review will focus on Ad
genome structure, oncolytic adenovirus construction, and their
therapeutic efficacy in combination with other anticancer agents.
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2 | ADENOVIRUS
The Ads are non‐enveloped viruses with a double‐stranded linear DNA
(about 36 kb) enclosed by an icosahedral protein capsid. The viral
genome consists of the early genes (E1, E2, E3, and E7) and late genes
(L1, L2, L3, L4, and L5) (Russell, 2000). To infect host cells, fiber knob
domain of Ads binds to coxsackie‐adenovirus receptor on the host cells,
then the interaction between arginine‐glycine‐aspartic acid (RGD)
motif on the penton base of the virus and cellular integrins helps
internalization of the virus (Alemany, 2014). Following the infection of
the target cell and disassembly of virus in early endosome, viral DNA
enters nucleus through pores with the aid of microtubules and dynein
and triggers transcription of early gene E1A, a subunit of E1 gene,
which controls the cell cycle and expression of the other early genes
(Alemany, 2009). In addition, because of binding to retinoblastoma (Rb),
E1A releases E2F from Rb, which is necessary for the synthesis of S
phase components (Russell, 2000). On the other hand, induction the
expression of p14ARF by E1A leads to accumulation of p53 in the cell
nucleus and therefore growth arrest (de Stanchina et al., 1998). To
overcome this problem, Ads encode another early gene called the E1B
gene, which has two major polypeptides: E1B19K and E1B55K (Cheng,
Wechman, McMasters, & Zhou, 2015). E1B19K, which is Bcl‐2
homolog, prevents E1A‐induced apoptosis through interfering with
Bak‐Bax interaction (Cuconati, Degenhardt, Sundararajan, Anschel, &
White, 2002). E1B55K is able to bind to p53, trigger its export into the
cytoplasm, and prime it for degradation (Querido et al., 1997). The Ad
E2 transcription unit encodes three different proteins which are
involved in viral DNA replication (Cheng et al., 2015). The E3 gene also
encodes several proteins such as E3–14.7K, E3‐gp19K, and RID, which
moderate infected host immune responses. The E3–14.7K protein
inhibits tumor necrosis factor (TNF)‐induced apoptosis and inflamma-
tion. The E3‐gp19K blocks transport of major histocompatibility
complex (MHC) class I to the cell surface by forming a complex with
MHC class I antigens. The RID protein which is composed of E3–104K
and E3–14.5K proteins inhibits FAS‐induced apoptosis (Wold &
Tollefson, 1998). The E4 gene products are involved in the regulation
of virus replication and transcription (Cheng et al., 2015). According to
functions of viral genes in host cells, genome modifications have been
applied to design Ads, which replicate selectively in tumors, so‐called
oncolytic adenoviruses (OAds). OAds exert their antitumor effects
through two mechanisms: direct lysis of cancerous cells and induction
of immune system responses (Howells, Marelli, Lemoine, & Wang,
2017). Following lysis of cancer cells, tumor antigen could be released
and lead to stimulation of the immune system (Ramesh et al., 2006).
This review focuses on OAd types, their antitumor effects, and
approaches that have been used in combination with OAds.
3 | ONCOLYTIC ADENOVIRUSES
Because the Ads are not able to selectively target tumor cells,
different modifications, including genetic manipulation, are needed for
this purpose. To achieve tumor selectivity, two main modifications on
Ads genome have been applied. The first modification uses small
deletions in the pivotal viral genes which are required for replication in
normal cells. These small deletions are complement with phenotype
alterations in cancer cells, thereby OAds replication is restricted to
tumor cells (Baker, Aguirre‐Hernández, Halldén, & Parker, 2018).
Bischoff et al. (1996) first used this approach and introduced ONYX‐
15 (dl1520), which lacks a functional E1B55K gene and replicates only
in cells with mutations in the p53 gene. Furthermore, additional
deletion in the E3B region sensitives ONYX‐15 against antiviral
immune responses (Ries & Korn, 2002). Also, deletion of other section
of the E1B gene, E1B19K, results in replication‐selective OAd. Because
E1B19K protein prevents FAS‐mediated apoptosis and the majority of
cancer cells have blocked the apoptosis pathway, the replication of Ad‐
DeltaE1B‐19K retracted in normal cells but not in cancer cells. In
addition, E1B19K protein abrogates E3‐ADP which prevents the
release of premature virus (Liu et al., 2004). Another approach to
achieve tumor selectivity with small deletions is a 24 base pair (bp)
deletion of the E1A gene (Fueyo et al., 2000; Heise et al., 2000a).
Because of this deletion and disruption of the Rb pathway in cancer
cells and increasing E2F production, cancer cells enter the S phase of
the cell cycle. Thus “delta‐24” OAds also are able to replicate and
release new adenoviral progeny. In most of the cancer cells and
because of a defective Rb/p16 pathway, rendering Rb binding
characteristic of E1A is unnecessary (Ulasov, Borovjagin, Schroeder,
& Baryshnikov, 2014). (Figure 1).
The second main modification on the Ads’ genome to produce
OAds is the insertion of tissue‐ or tumor‐specific promoters to
control viral replication. Rodriguez et al. (1997) first used this
approach by insertion of prostate‐specific antigen (PSA) promo-
ter for expression of E1A. Other tissue‐specific promoters also
have been used including tyrosinase for melanoma (Zhang et al.,
2002), α‐fetoprotein for liver cancer (Kim et al., 2002), and
carcinoembryonic antigen (CEA) for colorectal cancer (Li et al.,
2003). Similarly, some OAds express E1A under the control of the
telomerase reverse transcriptase (TERT) promoter against TERT‐
positive cancer cells (Li et al., 2016; Oh, Hong, Kwon, &
Yun, 2018).
4 | OAd IN COMBINATION WITH OTHER
AGENTS
Beside antitumor properties of OAds by itself, the combination with
other agents has been investigated to enhance their efficacy.
4.1 | OAd and immune checkpoint inhibitors
One of the new approaches that have been emerged in treating
various types of cancers is the use of inhibitors against immune
checkpoint proteins such as programmed cell death protein 1 (PD‐1)
and cytotoxic T lymphocyte‐associated 4 (CTLA‐4). Interactions of
PD‐1 and CTLA‐4 on the surface of cytotoxic T‐cells with their ligand
programmed death ligand‐1 (PD‐L1) and cluster differential 80
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(CD80)/cluster differential 86 (CD86) on antigen presenting cells
(APCs) help evasion of cancer cells from T lymphocytes (Dine,
Gordon, Shames, Kasler, & Barton‐Burke, 2017). Because of the
immunosuppressive tumor microenvironment, immune checkpoint
inhibition is less effective in some cancers (Sharma & Allison, 2015).
Interestingly, viral infection and replication during virotherapy
overcomes this repressive microenvironment and leads to T‐cell
activation against cancer neo‐antigens (Schumacher & Schreiber,
2015; Zamarin et al., 2014). Therefore, combining OAds with
checkpoint inhibitors is an attractive approach to cancer therapy.
Jiang et al. (2017) reported that combining Ad5‐Δ24‐RGDOX, which
expresses OX40L (an immune co‐stimulator) with anti‐PD‐L1 anti-
body in glioma‐bearing mice, increased long‐term survival rate up to
58%, this effect in antibody alone‐ and OAd alone‐treated groups
was 15% and 28%, respectively. Considering that adenovirus‐related
cell death is attributable to autophagy induction, Ad5‐Δ24‐RGDOX is
able to induce autophagy and release damage‐associated molecular
patterns such as high mobility group protein B1 (HMGB1) and ATP
which leads to the attraction of immune cells and infiltration of
lymphocytes at the tumor site (Jiang et al., 2017). Combination of
Pembrolizumab (anti‐PD‐1 antibody) and DNX‐2401 (Ad5‐Δ24‐RGD)
is under evaluation in a multi‐center Phase II clinical trial
(NCT02798406).
Because CTLA‐4 overexpression has been reported in several
cancers including colon cancer, melanoma, neuroblastoma, breast
cancer, and osteosarcoma (Contardi et al., 2005), CTLA‐4 blockage
using human monoclonal antibodies such as tremelimumab and
ipilimumab is a promising approach in activation of tumor‐specific T‐
cells (J. L. Huang, LaRocca, & Yamamoto, 2016). Using human
monoclonal CTLA‐4 antibody expressing OAd in four patients,
Hemminki group showed that Ad/3‐Δ24aCTLA4 is able to increase
production of IL‐2, a marker for T‐cell activation, and IFNγ (Dias
et al., 2012).
4.2 | OAds and stimulatory factors
To improve immune responses against the tumor, immunostimula-
tory factors such as granulocyte‐macrophage colony‐stimulating
factor (GM‐CSF), TNF‐α, Interleukin (IL)‐2, IL‐12, IL‐15, IL‐18, and
IL‐24 can be embedded into the genome of OAds (Cerullo et al.,
2010). One of the most effective immunostimulatory factors is GM‐
CSF, its antitumor properties could be related to stimulation of
dendritic cells (DCs) and direct recruitment of natural killer (NK) cells
(Dranoff, 2003). Because of off‐target activity and toxic effects of
systemic administration of GM‐CSF beside induction of myeloid‐
derived suppressor cells (MDSCs) and low concentration in the
tumor microenvironment (Koski et al., 2010; Serafini et al., 2004),
targeting of tumor cells using OAds has been shown to be able to
resolve mentioned problems to some extent. CG0070 is a con-
ditionally replicating OAd in which E1A and GM‐CSF expression
occur under E2F and E3 promoter in the Rb‐defective tumor cells.
Ramesh et al. (2006) reported that the cytotoxicity of CG0070 in Rb‐
defective bladder TCC cell lines was very high in comparison with
normal human cells. Also, GM‐CSF expression was 1,000‐fold higher
F IGURE 1 Mechanism of Ad‐Δ24 action. (a) When wild‐type Ad (Ad wt) infects a normal cell, E1A protein of Ad binds to Rb and inactivates
it. Following inactivation of Rb, E2F releases which results in cell cycle progress and viral replication. (b) When Ad‐Δ24 infects a normal cell, the
E1A protein is unable to bind to Rb. So, because of inactivation of E2F by Rb, the normal cell is unable to replicate thereby halting the
replication of the Ad‐Δ24 and cell lysis. (c) Because of the disruption of the Rb pathway and increase of E2F, infected cancer cell replicates,
which leads to the production of new Ad‐Δ24 progeny [Color figure can be viewed at wileyonlinelibrary.com]
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in CG0070‐treated bladder cell lines compared with normal cells.
Xenograft tumor models showed that intratumoral injection of
CG0070 significantly reduced tumor volume and induced apoptosis
of tumor cells. In addition, adenovirus hexon staining demonstrated
prolonged virus replication within the tumor mass. These antitumoral
responses could be related to high levels of GM‐CSF (Ramesh et al.,
2006). According to Bramante et al. (2015), using Ad5/3‐Δ24‐GM‐
CSF for infection of human melanoma cells stimulates the differ-
entiation of monocytes to macrophages. Cerullo et al. (2010) showed
that administration of Ad5‐Δ24‐GM‐CSF in cancerous patients
induces an immune response against survivin, a tumor‐associated
antigen, which suggests that combining cell lysis property of OAds
with GM‐CSF‐mediated recruitment and activation of DCs and NK
cells can break immunological tolerance (Cerullo et al., 2010). Cancer
cells and stroma cells produce transforming growth factor‐β2 (TGF‐
β2), which acts as an immunosuppressive molecule, because of
MDSCs stimulation, (Draghiciu, Lubbers, Nijman, & Daemen, 2015;
Wrzesinski, Wan, & Flavell, 2007) and an inducer for GM‐CSF‐
mediated DC maturation (Olivares et al., 2011; Wilson et al., 2011).
Accordingly, GM‐CSF and TGF‐β2 shRNA‐expressing OAd could
inhibit tumor growth more efficiently than GM‐CSF expressing OAd
in melanoma‐bearing mice (Kim et al., 2017). The capability of OAds
in dissemination through the bloodstream to distant uninjected
tumors following intratumoral injection could enhance their anti-
tumor efficacy. Surprisingly, the presence of OAds could be higher in
uninjected tumors compared with injected ones due to the prominent
antiviral responses in injected tumors (Bramante et al., 2014). Z. Liu
et al. (2017) used decorin (DCN) and GM‐CSF‐armed OAd (rAd.DCN.
GM) in mice model of colorectal cancer (CRC). According to results,
rAd.DCN.GM can reduce tumor growth, lung metastases, angiogen-
esis, and epithelial‐mesenchymal transition (EMT) as well as increase
DCs, CD8+ T‐cells, and perforin and Granzyme B secretion. Decorin,
a tumor suppressor gene, is downregulated in many cancers such as
CRC (Troup et al., 2003) and inhibitory effects of rAd.DCN.GM on
protumorigenic signals could be related to DCN overexpression in
the tumor microenvironment. In addition, DCN inhibits expression of
TGF‐β (Liu et al., 2017), which plays an essential role in regulating
immune tolerance by suppressing the maturation of DCs, NK cells,
and Th cells, inducing polarization of Th cells toward Th2 and the
polarization of macrophages toward M2, and inhibiting cytotoxicity
of CD8+ T‐cells (Flavell, Sanjabi, Wrzesinski, & Licona‐Limón, 2010;
Marcoe et al., 2012). Decorin also enhances OAd intratumoral spread
through binding to collagen and limiting collagen fibril size (Choi
et al., 2010).
The low toxicity of CG0070 has been reported in interim results
of Phase II study from patients with failed BCG therapy for non‐
muscle‐invasive bladder cancer (Packiam et al., 2018). Safety
evaluation of Ad5/3‐Δ24‐GM‐CSF in melanoma patients reported
fever, fatigue, dizziness, edema, rigors, and reduction in lymphocyte
numbers (Bramante et al., 2015). Kuryk et al. (2017) demonstrated
that repeated administration of ONCOS‐102 (Ad5/3‐Δ24‐GM‐CSF)
in hamster has no adverse effects including food consumption, body
weight, histopathology (for liver, kidney, and lung), hematology and
clinical chemistry parameters (such as liver enzymes activity
including LDH, ALT, and AST) and bio‐accumulation. They also
showed that following ONCOS‐102 administration, levels of neu-
tralizing antibodies (Nab) increase in hamster sera. The combination
with cyclophosphamide (CP) or changing the inoculation route
reduced Nab formation (Kuryk et al., 2017).
IL‐12 is another antitumor cytokine which is produced by
stimulated macrophages, DCs, monocytes, and activated B cells. It
has been shown that antitumor activity of IL‐12 is related to
enhancing the proliferation of both CTL and NK cells (Trinchieri,
Pflanz, & Kastelein, 2003), and stimulating the production of IFN‐γ
from those cells and increasing susceptibility of tumor cells to T‐cell‐
mediated cytotoxicity (Tahara et al., 1995). Y. S. Lee et al. (2006)
engineered E1B 55 kDa deleted OAds to express IL‐12 and B7‐1, a
costimulatory molecule on APCs, (YKL‐IL12/B7). They demonstrated
that intratumoral administration of 5 × 108 plaque‐forming units
(PFU) of YKL‐IL12/B7 in melanoma tumor‐bearing mice resulted in
tumor regression, the longevity of survival, increasing of IL‐12, and
IFN‐γ production, and augmentation of CD4+ and CD8+ T‐cells
infiltration into tumor tissues. Tumor regression capability of YKL‐
IL12/B7 could be related to increasing IFN‐γ secretion, as the crucial
downstream mediator of the IL‐12, which enhances immune
responses and increases tumor cells susceptibility to CTLs (Coughlin
et al., 1998). Interestingly, because of replicating vector systems,
using OAds compared to nonreplicating systems increase IFNγ levels
far greatly (7,289 pg/mg against 200 pg/mg) (Y. S. Lee et al., 2006;
Mazzolini et al., 1999). Increasing of IFNγ as a downstream mediator
of IL‐12 can inhibit angiogenesis (Yao et al., 1999), and W. Kim et al.
(2011) demonstrated that IL‐12 and GM‐CSF expressing OAd in
combination with radiotherapy decreased microvessel density. One
of the problems in the systematic administration of IL‐12 as an
antitumor agent is dose‐dependent toxicity (Leonard et al., 1997).
Intratumoral injection of IL‐12 expressing OAds solves this problem
besides high antitumor efficacy (Barajas et al., 2001; Y. S. Lee
et al., 2006).
Li et al. (2016) used CCL21 and IL21‐armed OAds in which E1A
expression was under the control of the TERT promoter. It has been
shown that CCL21 promotes chemoattraction of DCs and naive T‐
cells to the tumor site and increases antitumor activity (Zhao et al.,
2014). IL21 exerts its antitumor functions by inducing the activity of
NK, NKT, and CD8+ T‐cells (Santegoets, Turksma, Powell, Hooijberg,
& de Gruijl, 2013). Therefore, Ad‐CCL21‐IL21 was able to induce
migration, suppress tumor cell growth and increase CTL cytotoxicity
in vitro (Li et al., 2016). In another study by this group, Ad‐CD40L‐
CCL20 showed the same results (G. Liu et al., 2015). In addition to
oncolysis effects, antitumoral functions of Ad‐CD40L‐CCL20 could
be related to the induction of DC maturation and T‐cells activation
by CD40L and CCL20 (Fontecedro et al., 2010; Turner et al., 2010). It
has been shown that CD40‐CD40L interaction directly inhibits tumor
cell proliferation, induces apoptosis (Ghamande et al., 2001; Tong
et al., 2001), causes T‐cells expansion, increases IL‐12 production,
and enhances the cytotoxicity of T‐cell responses (Ghamande et al.,
2001; Tong & Stone, 2003; Tong et al., 2001).
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IL‐2, as an attractive molecule in gene therapy of cancers, has
shown its antitumor efficacy through stimulation of T‐cell prolifera-
tion and differentiation (Havunen et al., 2017). TNF‐α, like IL‐2, is not
only able to activate immune cells (Hirvinen et al., 2015), but also
produces other chemokines and cytokines, induces antitumor
inflammation (Balkwill, 2009; Mocellin, Rossi, Pilati, & Nitti, 2005),
and causes apoptosis and necrosis of cancer cells (Mocellin et al.,
2005). Havunen et al. (2017) engineered an OAd for expressing
human IL‐2 and TNF‐α (Ad5/3‐E2Fd24‐hTNFa‐IRES‐hIL12 or TILT‐
123). They reported 1 × 109 VPs as an optimal dose of TILT‐123 in
mice model of ovarian tumor and examined its efficacy in combina-
tion with tumor‐infiltrating lymphocyte (TIL) in the Syrian hamster
model. According to their results, a combination of TILT‐123 with TIL
is able to completely cure the animals and three months follow‐up
demonstrated that cured animals remained tumor free. Re‐challen-
ging of cured hamsters (with TILT‐123) protected the animals from
tumor growth which implies the formation of memory responses
(Havunen et al., 2017). Immunological immune responses could be
related to increasing of the T‐cell population following TILT
treatment (Tysome et al., 2012).
4.3 | OAd and DCs
The most important cells for antigen presentation are DCs. Following
antigen uptake, exogenous and endogenous antigens are presented
in MHC II and MHC‐I complexes, respectively. Tumor antigens could
be presented to CD8+ T‐cells in a process, so‐called cross‐presenta-
tion, in which exogenous antigens also are presented in MHC‐I
complexes (Bol, Schreibelt, Gerritsen, De Vries, & Figdor, 2016). To
induce specific T‐cell responses against tumors, DC‐based vaccina-
tion is emerging as a hopeful strategy (Fong & Engleman, 2000). In
this strategy, DCs have exposed to tumor‐associated antigens (TAA)
in many forms including peptide, protein, DNA, RNA, or whole tumor
lysate (Timmerman & Levy, 1999). Immunosuppressive tumor
microenvironment can minimize DC‐based vaccine efficacy by the
production of mediators such as IL‐10, TGF‐β, and vascular
endothelial growth factor (VEGF) (Gabrilovich, 2004). Thus, combin-
ing DC‐based vaccines with other approaches to increase the efficacy
is common. Zafar et al. (2017) inserted CD40L gene into Ad3 genome
for stimulating DCs and human telomerase reverse transcriptase
(hTERT) telomerase for selective replication in cancer cells (Ad3‐
hTERT‐CMV‐hCD40L). They demonstrated that intravenous admin-
istration of Ad3‐hTERT‐CMV‐hCD40L maturated and activated DCs
due to the increased expression of CD40L. In addition, Ad3‐hTERT‐
CMV‐hCD40L was able to kill tumor cells because of OAd‐induced
oncolysis and hCD40L‐induced apoptosis (Zafar et al., 2017). In
another study, IL‐12 and GM‐CSF expressing OAds (Ad‐ΔB7/IL12/
GM‐CSF) + DCs showed stronger tumor inhibition efficacy and long‐
term survival rates through decreased VEGF expression and
promoted DC function in melanoma‐bearing mice (Zhang et al.,
2011). VEGF, as a primary target in cancer therapy, is the most
important growth factor in tumor angiogenesis, by which sprouting
new vessels from pre‐existing ones supplies nutrients and oxygen to
all tumor cells and guarantees their growth and survival (Goradel
et al., 2017, 2018). In addition, increased levels of IL‐12 following Ad‐
ΔB7/IL12/GM‐CSF + DC administration could enhance Th1 re-
sponses and cytotoxicity of T‐cells and NK cells (Gerosa et al.,
2002). Part of the anti‐tumoric effects of this combination can be due
to the induction of apoptosis of Treg cells by IL‐12 (Kilinc et al.,
2006). It has been shown that antitumor efficacy of high dose OAds
in combination with DCs is more potent (Zhang et al., 2011). In
another study, IL‐12 and 4‐1BB ligand (4‐1BBL) co‐expressing OAd
(Ad‐ΔB7/IL‐12/4‐1BBL) plus DCs showed more potent antitumor and
antimetastatic effects compared to Ad‐ΔB7. Moreover, antitumor
effects of Ad‐ΔB7/IL‐12/4‐1BBL + DCs was due to increased Th1
population, migration of DCs to the tumor site, and CTL activity. 4‐
1BBL is a costimulatory molecule on APCs including DCs, B cells, and
macrophages, which following interaction with its receptor (4‐1BB)
enhances Th1 and cytotoxic T‐cells development (J. H. Huang
et al., 2010).
Because of DCs inactivation and rapid clearance of Ads, repeated
administration of both DCs and OAds is proposed to increase
therapeutic effects of their combination (Chang et al., 2011), which
also results in the induction of neutralizing antibodies and toxic
effects. To resolve these problems, using biodegradable hydrogel
carriers has been studied as a sustained co‐delivery method. Oh et al.
(2017) reported that OAd +DC/gel‐treated lung tumor‐bearing mice
inhibited tumor growth greater than OAd and OAd +DC groups and
induced tumor‐specific immune responses. Their further analysis
demonstrated that the concentration of OAds and DCs was higher in
OAd +DC/gel‐treated group for a long time, which implies that the
gel carrier enhanced persistence of OAds and DCs.
4.4 | OAd and chemotherapy
It has been shown that cyclophosphamide (CP) alone, as a
chemotherapy drug, was not able to reduce tumor growth in
melanoma mice model, whereas low‐dose CP combined with Ad5/
3‐Δ24‐GM‐CSF led to complete tumor regression (Bramante et al.,
2014). The effectiveness of using mentioned combinational approach
could be related to the reduction of regulatory T‐cells (Tregs)
(Cerullo et al., 2010; Koski et al., 2010) and inhibitory effects of CP
on angiogenesis (Wang et al., 2012).
Administration of intratumoral ONYX‐015 and intravenous
cisplatin and 5‐FU in head and neck and ovarian cancer xenograft
mice models inhibited tumor growth and prolonged survival period
over single treatment. It was shown that medication efficacy
depended on treatment sequencing. In all cases, OAd treatment
before chemotherapy or simultaneous treatment showed better
results compared with chemotherapy followed by OAd, which
suggests that viral replication enhances chemosensitivity of tumors
(Heise, Lemmon, & Kirn, 2000b). Deletion of E3 region genes in
ONYX‐015 enhanced TNF induction and TNF‐mediated cell killing
(Dimitrov et al., 1997). In addition, chemotherapy did not affect viral
replication, and no increase in toxicity was demonstrated (Heise
et al., 2000b). Similar construct to ONYX‐015, H101, which was
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generated by Sunway Biotech company (Lu et al., 2004; Yu & Fang,
2007) and was approved in China in 2005 for the treatment of
nasopharyngeal carcinoma improved positive response rate in
combination with chemotherapy (79%) in Phase III clinical trial,
whereas positive responses of alone chemotherapy treatment was
40% (Garber, 2006). Other products related to H101 have also
developed by this company. In H102 construct, the alpha‐fetoprotein
promoter is embedded upstream of Ad E1A gene which targets
selectively hepatocarcinoma cells and H103 carries the heat shock
protein 70 (HSP70) gene as tumor antigen for stimulating immune
responses (Cheng et al., 2015).
Gemcitabine as a chemotherapy agent exerts its antitumor
functions through blockade of DNA synthesis, induction of cell death,
activation of DNA damage responses, and inhibition of cell prolifera-
tion (Leitner et al., 2009). Synergistic efficacy of gemcitabine‐based
chemotherapy in combination with OAds has been reported (Bhatta-
charyya, Francis, Eddouadi, Lemoine, & Hallden, 2011; Onimaru et al.,
2010). Although gemcitabine can block virus replication, it enhances
cell killing activity by inducing a delay in G1/S cell cycle progression
(Leitner et al., 2009). Similar to gemcitabine, mitomycin in combination
with OAds arrests cell cycle in the S phase (Li et al., 2017). It has been
shown that the synergistic increase in apoptotic response in
combination therapy could be due to increased sensitivity of tumor
cells to chemotherapy in the presence of OAds (Lee et al., 2003; Li
et al., 2017). In contrast to gemcitabine, the synergistic antitumor
efficacy of doxorubicin combined with OAds is due to the positive
effects of doxorubicin on virus replication. In addition, doxorubicin is
able to induce death of immunogenic tumor cells and subsequent
recruitment and activation of DCs because of local production of GM‐
CSF by GM‐CSF‐armed OAds (Siurala et al., 2015). Synergistic
antitumor effect of doxorubicin could also be related to improving
the infectious efficiency of OAds (Li et al., 2018). In another study,
Fang et al. (2013) examined the antitumor properties of the IL‐24
expressing OAd (ZD55‐IL‐24) combined with Paclitaxel (PTX) in breast
cancer cells. This combination reduced tumor cell growth, and PTX
increased OAd uptake without affecting its replication. It was also
reported that ZD55‐IL‐24 and PTX combination could increase
apoptotic protein levels and caspase proteins.
4.5 | OAd as an active carrier
One approach to stimulate the immune system against tumor
antigens is introducing antigen‐encoding genes into the adenoviral
vectors, which requires genomic manipulation of the virus (Sorensen,
Holst, Pircher, Christensen, & Thomsen, 2009). In a novel approach,
namely PeptiCRAd, antigenic peptides are not expressed by the
adenovirus, but MHC‐I tumor epitopes are loaded on OAds based on
electrostatic interactions between the negative surface charge of
OAd and positively charged epitopes (Capasso et al., 2016; Garofalo
et al., 2016). Preparation of this system is rapid and versatile, which
does not need genetic or chemical modifications of the virus
(Capasso et al., 2016). PeptiCRAd can also be used as a carrier for
the delivery of many bioactive drugs (Garofalo et al., 2016).
L‐carnosine, a histidine dipeptide, has significant anticancer
activity, but its antiproliferative effect requires a high dose (Iovine,
Iannella, Nocella, Pricolo, & Bevilacqua, 2012; Renner et al., 2010). To
overcome this limitation, Garofalo et al. (2016) used OAd as a carrier
to facilitate carnosine entry into the cancer cells. They added six
lysine residues to create a positive charge at the C‐terminus of
carnosine to load it on the OAd (Carnosine6K‐coated OAd).
Carnosine6K‐coated OAds enhanced anticancer efficacy both in
vitro and in vivo, and Carnosine6K increased transduction efficacy of
OAds. Interestingly, separate usage of Carnosine6K and OAd could
not enhance efficacy, which implies that L‐carnosine employs OAd as
a carrier to enhance cell entry (Garofalo et al., 2016). In another
study by this group, they used polylysine (polyK) for loading MHC‐I
peptides of melanoma on OAd (Ad5‐Δ24‐CpG). Intratumoral injec-
tion of PeptiCRAd reduced tumor growth and increased antitumor
immunity significantly in a murine model of melanoma. Increased
antitumor immune responses could be due to the APC maturation
and TLR‐9 activation following PeptiCRAd administration. In addi-
tion, using multivalent PeptiCRAd showed enhanced antitumoral
effects compared to monovalent one (Capasso et al., 2016).
5 | CLINICAL TRIALS
Many clinical studies have been conducted on the effectiveness of
OAds in various types of cancers and Table 1 lists ongoing studies.
6 | CHALLENGES AND SOLUTIONS
Despite remarkable results, application of OAd in cancer therapy is
faced with serious challenges. Overexpression of PD‐L1 following
treatment with OAd and IFNγ secretion is one of the challenges, and
combining anti‐PD‐L1 antibody with OAd therapy has primarily
addressed the issue (Jiang et al., 2017). Also, in most solid tumors,
because of the presence of extracellular matrix, noncancerous cells in
tumor microenvironment such as fibroblasts and neovascular
formation, the penetration of the OAds into the tumor bulk is
hampered (Yamamoto, Nagasato, Yoshida, & Aoki, 2017). Various
strategies have been used to overcome this problem including using
epithelial junction opener (Yumul et al., 2016), vasoactive and
metalloproteinase (Kaufman, Kohlhapp, & Zloza, 2015).
Antiviral immune responses against OAds and liver toxicity of the
virus could limit their efficacy and shorten Ads lifespan (Jung et al.,
2017). Surface modification and polymeric coating of the virus have
been used to overcome these limitations (Choi et al., 2015a; Choi,
Lee, Yun, & Kim, 2015b). To overcome hepatic sequestration and
preserving form Nab, Chen et al. (2016) used PEG/Lipid/calcium
phosphate (PLC) delivery system for IL‐24 carrying OAd. They
demonstrated that using a PLC system reduced liver sequestration
and systemic toxicity, and protected OAd form Nabs. Encapsulation
of OAds in a gelatin hydrogel has been shown to increase virus
concentration in tumor microenvironment for a long time, increase
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antitumor efficacy and decrease antiviral immune responses (Jung
et al., 2017).
Furthermore, adaptive Ads are another resolution to circumvent
antiviral immunity. According to this strategy, nonhuman adenoviral
vectors have been applied as alternative vectors (Bangari & Mittal,
2006). The advantages of nonhuman vectors are: (a) absence of pre‐
existing neutralizing immunity; (b) altered tissue tropism and (c)
efficient transduction of human cells (Uusi‐Kerttula, Hulin‐Curtis,
Davies, & Parker, 2015). There are some nonhuman Ad serotypes
including canine Ad2 (CAV‐2), porcine Ad3, bovine Ad3, simian Ads,
murine Ad1, and fowl Ads, which have been used as gene delivery
vehicles (Lopez‐Gordo, Podgorski, Downes, & Alemany, 2014). It has
been shown that approximately 98% of healthy serum samples did
not contain detectable levels of Nabs against CAV‐2 (Kremer, Boutin,
Chillon, & Danos, 2000). Also, the proliferation of CD4+ memory cells
(TM) and CD8
+ TM against CAV‐2 is significantly lower than against
human Ad5 (Perreau & Kremer, 2005). These advantages of nonhu-
man vectors could translate into human clinical trials.
Another important variable affects the efficacy of OAds is the
culturing system. It has been reported that using Matrigel‐based
cultures are more efficient than conventional culture systems.
Matrigel‐derived viruses could suppress all tumor growth, while
conventional culture‐derived viruses are 50% effective (Kuhn
et al., 2017).
7 | CONCLUSIONS
Regarding the ease of production and modification compared with
other viruses, besides interesting outcomes of the application of
OAds as a therapeutic agent in cancer therapy, alone or in
combination with other agents, it has attracted scientists’ attention,
and several clinical trials are undergoing worldwide. However, the
further expansion of OAd application as therapeutic agent requires
more attention to the challenges in this field, and involvement of
multidisciplinary approaches from computational biology to
chemistry and nanotechnology may largely address the problems.
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